AstraZeneca

We continue to make strides with our early oncology development pipeline. At #AACR25, we disclosed data from six new assets across a range of modes of actions, including four in prostate cancer – a disease with immense unmet needs. These findings show the strength of our early portfolio, fueling our ambition to transform outcomes for patients with cancer. #Oncology #Immunotherapy #ProstateCancer

We have an exciting update: AstraZeneca's partnership with Qure.ai has reached its target of enabling 5 million routine chest X-rays to be assessed by #AI for #LungCancer risk, across 20 countries in Latin America, Asia, the Middle East and Africa. This initiative aligns with our commitment to the World Economic Forum's EDISON Alliance 1 Billion Lives Challenge and reflects our dedication to addressing health challenges in underserved communities with innovative technologies. Learn more: https://learn.az/60452vO17 #InnovationInHealthcare

#News for #Investors and #Media📈 We continued our strong growth momentum into 2025 with Total Revenue increasing by 10%, driven by double-digit growth across Oncology/ Haematology and BioPharmaceuticals. Swipe below to discover more. #AZN #FinancialResults

It’s #DNADay, celebrating over 70 years of groundbreaking advancements in genomics—from the discovery of DNA's double helix structure to sequencing the first complete human genome. We’re harnessing these advancements to generate insights that can help create pioneering, innovative medicines that target the root causes of disease. As we reflect on the impact genomics has had, we’re also looking ahead to the next generation of scientific change-makers. Our global STEM programmes bring the story of DNA to life with inspiring activities for young minds. Together, let’s help ignite the future of scientific discovery. #WhatScienceCanDo

The Financial Times has listed us as Europe’s Climate Leaders for our bold action to mitigate climate change. We’re first among pharma companies and are recognised for the fifth consecutive year! We’re decarbonising our business to achieve net zero and are embedding sustainability into everything we do – from the lab to the patient. We’ve reduced our Scope 1 and 2 greenhouse gas emissions by 77.5% since 2015, while more than doubling our business. And we’re not stopping there, we’ve: 🔌 Reduced energy consumption by 20% 💡 Doubled energy productivity ⚡ 97% of our electricity is from renewables 🌡️ Launched clean heat partnerships in China, the UK and the US 🔋 Switched 63% of our global fleet to EVs Together with our partners and suppliers, we're on a mission to decarbonise our value chain for a healthier future for people, society, and our planet. Financial Times Europe's Climate Leaders: https://learn.az/60492dc8d

Small differences in DNA can have a big impact on health. We decode DNA from a variety of understudied communities around the world to develop medicines that benefit a broad range of people. #WhatScienceCanDo

Small details can help make a big difference to people’s health. That’s why we’re decoding disease by studying over 1.5 million genomes from communities around the world. #WhatScienceCanDo

Important update: We will share our Q1 2025 performance update at 07:00 GMT on Tuesday 29 April 2025.        An accompanying webcast for investors and analysts will take place at 11:45 GMT – you can register to attend virtually here: https://lnkd.in/etgGA7eq

“The power of partnership is central to delivering the change that is needed to ensure health systems are both delivering for patients today, while remaining resilient enough to tackle the challenges of tomorrow,” shares Alex de Giorgio-Miller, SVP BioPharmaceuticals Medical. Learn more about our efforts to drive improvements in patient outcomes here: https://learn.az/60432HKnT

In an era where AI is reshaping our work environment, we’re empowering our employees with cutting-edge skills and insights. Learn how we’re building a future-ready workforce prepared to thrive in the age of AI: https://learn.az/60412z8QJ #ThrivingInTheAgeofAI